Kisoo Pahk1, Seunghong Rhee1, Jaehyuk Cho1, Minhee Seo1, Sinae Lee2, Taegyu Park2, Soyeon Park2, Eunsub Lee2, Kyung Hwa Park3, Chulhan Kim4, Jae Seon Eo2, Sungeun Kim1, Jae Gol Choe5. 1. Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea. 2. Department of Nuclear Medicine, Korea University Guro Hospital, Seoul, South Korea. 3. Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, South Korea. 4. Department of Nuclear Medicine, Korea University Ansan Hospital, Ansan, South Korea. 5. Department of Nuclear Medicine, Korea University Anam Hospital, Seoul, South Korea choejg@korea.ac.kr.
Abstract
AIM: The aim of this study was to prove the diagnostic value of interim 18F-Fluorodeoxyglucose-positron-emission tomography combined with computed tomography (PET/CT) scan for predicting pathological complete response (pCR) compared to other factors in neoadjuvant chemotherapy. PATIENTS AND METHODS: Twenty-seven patients with breast cancer were included in this retrospective study. They all underwent scheduled neoadjuvant chemotherapy. Patients underwent PET/CT at baseline, mid-point (interim), and preoperatively (after completion of chemotherapy). The metabolic response was calculated as follows: ΔStandardized uptake value (SUV)(%)=(1st SUV(max)-2nd SUV(max))/1st SUV(max) × 100. RESULTS: The change in SUVmax between baseline and interim PET/CT scans was significantly larger than between interim and preoperative PET/CT scan. An optimal cut-off ΔSUV value of 78.3% was proposed for discriminating patients with pCR from those without pCR. Metabolic CR, defined as a change of SUV(max) greater than the cut-off value, can predict pCR according to univariate analysis (p=0.012; Relative risk (RR)=25.3). Furthermore, metabolic CR was the most powerful factor for predicting pCR than other possible factors according to multivariate analysis (p=0.003). CONCLUSION: It is possible to use interim (18)F-FDG PET-CT as an effective method to predict early response in patients with breast cancer treated with neoadjuvant chemotherapy. Copyright
AIM: The aim of this study was to prove the diagnostic value of interim 18F-Fluorodeoxyglucose-positron-emission tomography combined with computed tomography (PET/CT) scan for predicting pathological complete response (pCR) compared to other factors in neoadjuvant chemotherapy. PATIENTS AND METHODS: Twenty-seven patients with breast cancer were included in this retrospective study. They all underwent scheduled neoadjuvant chemotherapy. Patients underwent PET/CT at baseline, mid-point (interim), and preoperatively (after completion of chemotherapy). The metabolic response was calculated as follows: ΔStandardized uptake value (SUV)(%)=(1st SUV(max)-2nd SUV(max))/1st SUV(max) × 100. RESULTS: The change in SUVmax between baseline and interim PET/CT scans was significantly larger than between interim and preoperative PET/CT scan. An optimal cut-off ΔSUV value of 78.3% was proposed for discriminating patients with pCR from those without pCR. Metabolic CR, defined as a change of SUV(max) greater than the cut-off value, can predict pCR according to univariate analysis (p=0.012; Relative risk (RR)=25.3). Furthermore, metabolic CR was the most powerful factor for predicting pCR than other possible factors according to multivariate analysis (p=0.003). CONCLUSION: It is possible to use interim (18)F-FDG PET-CT as an effective method to predict early response in patients with breast cancer treated with neoadjuvant chemotherapy. Copyright
Authors: Sara Sheikhbahaei; Tyler J Trahan; Jennifer Xiao; Mehdi Taghipour; Esther Mena; Roisin M Connolly; Rathan M Subramaniam Journal: Oncologist Date: 2016-07-08
Authors: P Brandmaier; S Purz; K Bremicker; M Höckel; H Barthel; R Kluge; T Kahn; O Sabri; P Stumpp Journal: PLoS One Date: 2015-11-09 Impact factor: 3.240